



**STATE OF NEVADA
OFFICE OF THE ATTORNEY GENERAL
BUREAU OF CONSUMER PROTECTION**

2025 ANNUAL REPORT FOR
CONTINGENT FEE CONTRACTS FOR LEGAL SERVICES
FOR THE 2024 CALENDAR YEAR

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	2
II. Contingent Fee Contracts	2
A. Opioid Investigation and Litigation Contingent Fee Contract	2
1. Name and Address of Retained Law Firm	2
2. Nature and Present Status of Matter that is the Subject of the Contract.....	2
3. Name of Each Party to the Matter	3
4. Amount of Recovery Obtained in the Matter	4
5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained	4
6. Amount of Any Fee Paid pursuant to the Contract.....	4
B. Social Media Platforms Investigation and Litigation Contingent Fee Contract.....	5
1. Name and Address of Retained Law Firm	5
2. Nature and Present Status of Matter that is the Subject of the Contract.....	5
3. Name of Each Party to the Matter	6
4. Amount of Recovery Obtained in the Matter	6
5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained	7
6. Amount of Any Fee Paid pursuant to the Contract.....	7
III. Determinations and Attachments.....	8
IV. Contact.....	8

I. Introduction

Pursuant to Nevada Revised Statutes (“NRS”) 228.1118, the Office of the Attorney General hereby submits this 2024 annual report to the Director of the Legislative Counsel Bureau, for transmittal to the Majority Leader of the Senate and the Speaker of the Assembly, describing the use of the contingent fee contracts entered into by the Office of the Nevada Attorney General for the proceeding calendar year. This 2025 Annual Report covers the 2024 calendar year.

II. Contingent Fee Contracts

A. Opioid Investigation and Litigation Contingent Fee Contract

Pursuant to NRS 228.111 *et seq.*, a contract relating to retained legal services for the Opioid Investigation and Litigation (“Opioid Contract”) was approved by the Interim Finance Committee on January 30, 2019, solicited through the Nevada State Purchasing Division, and entered into by the Office of the Nevada Attorney General Bureau of Consumer Protection on May 2, 2019. The Opioid Contract and related information is posted on the website of the Office of the Nevada Attorney General, and can be found here:

https://ag.nv.gov/Hot_Topics/Opioid_Epidemic/

1. Name and Address of Retained Law Firm

Eglet Law Group, LLP dba Eglet Adams Eglet Ham Henriod
400 South 7th Street, 4th Floor
Las Vegas Nevada 89101

2. Nature and Present Status of Matter that is the Subject of the Contract

The Opioid Investigation and Litigation (“Opioid Investigation and Litigation”) seeks to hold companies and individuals accountable for their contributions to the opioid epidemic in the State of Nevada.

Case No. A-19-796755-B:

The State commenced litigation by Amended Complaint on June 27, 2019, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-19-796755-B. The State filed a Second Amended Complaint on March 9, 2021. This matter resulted in numerous settlements and is stayed by Federal Bankruptcy courts for certain defendants.

Case No. A-24-885923-C:

The State commenced litigation by Complaint on January 26, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-885923-C. This matter was removed to the United States District Court for the District of Nevada and is pending a decision on a motion to remand to State court.

3. Name of Each Party to the Matter

Case No. A-19-796755-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): MCKESSON CORPORATION; CARDINAL HEALTH INC.; CARDINAL HEALTH 105, INC.; CARDINAL HEALTH 108, LLC; CARDINAL HEALTH 110, LLC; CARDINAL HEALTH 200, LLC; CARDINAL HEALTH 414, LLC; CARDINAL HEALTH PHARMACY SERVICES, LLC; AMERISOURCEBERGEN DRUG CORPORATION; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; WALGREEN EASTERN CO., INC.; WALMART INC.; CVS PHARMACY, INC.; TEVA PHARMACEUTICALS USA.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; CEPHALON, INC.; ACTAVIS PHARMA, INC.; ALLERGAN FINANCE, LLC (fka ACTAVIS, INC. fka WATSON PHARMACEUTICALS, INC.); WATSON LABORATORIES, INC.; ACTAVIS, LLC; PURDUE PHARMA L.P.; PURDUE PHARMA, INC.; PURDUE HOLDINGS, L.P.; THE PURDUE FREDERICK COMPANY, INC.; P.F. LABORATORIES, INC.; RICHARD S. SACKLER; JONATHAN D. SACKLER, MORTIMER D.A. SACKLER; KATHE A. SACKLER; ILENE SACKLER LEFCOURT; DAVID A. SACKLER; BEVERLY SACKLER; THERESA SACKLER; PLP ASSOCIATES HOLDINGS L.P.; ROSEBAY MEDICAL COMPANY L.P.; BEACON COMPANY; ENDO HEALTH SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.; PAR PHARMACEUTICAL, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; SPECGX LLC; JOHNSON & JOHNSON; JANSSEN PHARMACEUTICALS, INC.; NORAMCO, INC.; CVS TN DISTRIBUTION LLC; LONGS DRUG STORE CALIFORNIA LLC; AMERICAN DRUG STORES; STEVEN A. HOLPER; STEVEN A. HOLPER MD PROFESSIONAL CORPORATION; HOLPER OUT-PATIENTS MEDICAL CENTER, LTD.; ROBERT GENE RAND; RAND FAMILY CARE LLC; DEVENDRA I. PATEL; PATEL NORTH EASTERN NEVADA CARDIOLOGY PC; HORACE PAUL GUERRA IV; ALEJANDRO JIMINEZ INCERA; ROBERT D. HARVEY; INCERA-IUVENTUS MEDICAL GROUP PC; INCERA LLC; DOE ENTITIES 1-10.

Case No. A-24-885923-C:

Plaintiff(s): STATE OF NEVADA

Defendant(s): OPTUM, INC.; OPTUMRX, INC.; OPTUMINSIGHT LIFE SCIENCES, INC.; OPTUMINSIGHT, INC.; UNITEDHEALTH GROUP, INC.; THE LEWIN GROUP, INC.; EVERNORTH HEALTH, INC.; EXPRESS SCRIPTS, INC.; EXPRESS SCRIPTS ADMINISTRATORS, LLC; ESI MAIL PHARMACY SERVICE, INC.; EXPRESS SCRIPTS PHARMACY, INC.; EXPRESS SCRIPTS SPECIALTY DISTRIBUTION SERVICES, INC.; MEDCO HEALTH SOLUTIONS, INC.; ELEVANCE HEALTH, INC.; CARELONRX, INC.; CARELON INSIGHTS, INC.; DOE ENTITIES 1-10.

4. Amount of Recovery Obtained in the Matter

Total recoveries for the Opioid Investigation and Litigation are made pursuant to the Opioid Contract and One Nevada Agreement on Allocation of Opioid Recoveries (“One Nevada Agreement”), which can be found here: https://ag.nv.gov/Hot_Topics/Opioid_Epidemic/

The One Nevada Agreement is an agreement entered into by the State of Nevada, every Nevada county, and each Nevada city and district that has active opioid-related litigation, for the purpose of fairly and equitably allocating recoveries in their respective opioid litigations.

Case No. A-19-796755-B:

The amount of recoveries obtained, including the amount of recoveries for the 2024 calendar year, are depicted in the attached Exhibit A - Chart 1 and Exhibit B - Chart 2.

Exhibit A - Chart 1 illustrates the total amount of recoveries actually received and anticipated to be received through settlements and bankruptcies.

Exhibit B - Chart 2 illustrates the amount of recoveries allocated to the Fund for a Resilient Nevada established pursuant to NRS 433.732.

Case No. A-24-885923-C:

There were no recoveries obtained during the 2024 calendar year.

5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained

Case No. A-19-796755-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

Case No. A-24-885923-C:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

6. Amount of Any Fee Paid pursuant to the Contract

A contingency fee has been negotiated that is dependent on the amount of recovery for the Opioid Investigation and Litigation.

Case No. A-19-796755-B:

The amount of attorney fees paid, including the amount of attorney fees paid during the 2024 calendar year, by the State of Nevada for the recoveries that have been obtained are presented in the attached Exhibit B - Chart 2.

Case No. A-24-885923-C:

There were no amount of attorney fees paid during the 2024 calendar year.

B. Social Media Platforms Investigation and Litigation Contingent Fee Contract

Pursuant to NRS 228.111 *et seq.*, a contract relating to retained legal services for the Social Media Platforms Investigation and Litigation (“SMP Contract”) was approved by the Interim Finance Committee on October 11, 2023, solicited through the Nevada State Purchasing Division, and entered into by the Office of the Nevada Attorney General Bureau of Consumer Protection on December 4, 2023. The SMP Contract and related information is posted on the website of the Office of the Nevada Attorney General, and can be found here:

https://ag.nv.gov/Hot_Topics/Social_Media_Platforms_Investigation_and_Litigation/

1. Name and Address of Retained Law Firm

Nachawati Law Group	WHLaw	Kemp Jones, LLP
5489 Blair Road	1 Riverfront Place, Suite 745	3800 Howard Hughes Pkwy
Dallas, TX 75231	North Little Rock, AR 72114	Seventeenth Floor
		Las Vegas, NV 89169

2. Nature and Present Status of Matter that is the Subject of the Contract

The Social Media Platforms Investigation and Litigation (“SMP Investigation and Litigation”) seeks to hold companies and individuals accountable for their contributions to the harms, risks, and impacts to the State of Nevada and its residents, particularly its youth, from social media platforms. The State commenced litigation in the SMP Investigation and Litigation as follows:

Case No. A-24-886110-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886110-B. The State filed an Amended Complaint on November 21, 2024. This matter is in motion practice and discovery.

Case No. A-24-886113-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886113-B. This matter is in motion practice and discovery.

Case No. A-24-886115-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886115-B. The State filed an Amended Complaint on November 27, 2024. This matter is in motion practice and discovery.

Case No. A-24-886120-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886120-B. The State filed an Amended Complaint on November 27, 2024. This matter is in motion practice and discovery.

Case No. A-24-886127-B:

The State commenced litigation by Complaint on January 30, 2024, in the Eighth Judicial District Court in and for the County of Clark, Case No. A-24-886127-B. The State filed an Amended Complaint on July 9, 2024, and a Second Amended Complaint on November 15, 2024. This matter is in motion practice and discovery.

3. Name of Each Party to the Matter

Case No. A-24-886110-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.

Case No. A-24-886113-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): SNAP, INC.

Case No. A-24-886115-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.

Case No. A-24-886120-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): META PLATFORMS, INC. f/k/a FACEBOOK, INC.; INSTAGRAM, LLC

Case No. A-24-886127-B:

Plaintiff(s): STATE OF NEVADA

Defendant(s): TIKTOK, INC.; BYTEDANCE INC.; BYTEDANCE LTD.; TIKTOK, LTD.; TIKTOK LLC

4. Amount of Recovery Obtained in the Matter

Case No. A-24-886110-B:

There were no recoveries obtained during the 2024 calendar year.

Case No. A-24-886113-B:

There were no recoveries obtained during the 2024 calendar year.

Case No. A-24-886115-B:

There were no recoveries obtained during the 2024 calendar year.

Case No. A-24-886120-B:

There were no recoveries obtained during the 2024 calendar year.

Case No. A-24-886127-B:

There were no recoveries obtained during the 2024 calendar year.

5. Amount of Costs and Expenses Paid in the Prosecution of the Matter for which No Recovery was Obtained

Case No. A-24-886110-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

Case No. A-24-886113-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

Case No. A-24-886115-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

Case No. A-24-886120-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

Case No. A-24-886127-B:

There were no amount of costs and expenses that have been paid for which no recovery was obtained during the 2024 calendar year.

6. Amount of Any Fee Paid pursuant to the Contract

A contingency fee has been negotiated that is dependent on the amount of recovery for the SMP Investigation and Litigation.

Case No. A-24-886110-B:

There were no amount of attorney fees paid during the 2024 calendar year.

Case No. A-24-886113-B:

There were no amount of attorney fees paid during the 2024 calendar year.

Case No. A-24-886115-B:

There were no amount of attorney fees paid during the 2024 calendar year.

Case No. A-24-886120-B:

There were no amount of attorney fees paid during the 2024 calendar year.

Case No. A-24-886127-B:

There were no amount of attorney fees paid during the 2024 calendar year.

III. Determinations and Exhibits

- There were no Determinations made in calendar year 2024.
- Exhibit A - Chart 1
- Exhibit B - Chart 2

IV. Contact

For additional information or questions, please contact Mark J. Krueger, Chief Deputy Attorney General, Office of the Nevada Attorney General, Bureau of Consumer Protection, at (775) 684-1298 or mkrueger@ag.nv.gov.

EXHIBIT A - CHART 1

Opioid Settlement and Bankruptcy Actual and Estimated Annual Recoveries and Allocations Pursuant to the One Nevada Agreement							
(assumes no default in payments)							
(CMS Medicaid costs, if any, not deducted)							
(assumes no administrative fees for court appointed third-party administrators)							
Settlement/Bankruptcy Name	Estimated/Actual Recovery Year	Estimated/Actual Recovery Month	Recoveries	Costs	Attorney Fees	Common Benefit Fund (CBF)	Net Allocation
McKinsey (State)	2021	September	\$ 45,000,000.00	\$ 16,538,249.51	\$ 5,407,732.59	\$ -	\$ 23,054,017.90
Janssen - J&J	2022	April	\$ 50,833,353.00	\$ 8,397,545.43	\$ 7,037,053.92	\$ -	\$ 35,398,753.65
Distributors	2022	August	\$ 9,897,161.96	\$ -	\$ 1,641,228.64	\$ -	\$ 8,255,933.32
Distributors	2022	September	\$ 10,401,434.73	\$ -	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
American Drug Stores	2022	November	\$ 1,500,000.00	\$ -	\$ 337,815.52	\$ -	\$ 1,162,184.48
Mallinckrodt (Bankruptcy)	2022	November	\$ 1,849,733.70	\$ -	\$ 416,579.22	\$ -	\$ 1,433,154.48
Mallinckrodt (Bankruptcy)	2022	November	\$ 40.00	\$ -	\$ -	\$ -	\$ 40.00
Distributors	2023	July	\$ 10,401,434.73	\$ -	\$ 1,724,851.29	\$ -	\$ 8,676,583.44
Allergan	2023	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
CVS (Costs)	2023	August	\$ 4,000,000.00	\$ 4,000,000.00	\$ -	\$ -	\$ -
CVS	2023	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2023	August	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
Mallinckrodt (Bankruptcy)	2023	October	\$ -	\$ -	\$ (416,579.22)	\$ -	\$ 416,579.22
Mallinckrodt (Bankruptcy)	2023	December	\$ 2,176,204.35	\$ -	\$ -	\$ -	\$ 2,176,204.35
Walgreens	2023	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Teva (Costs)	2024	January	\$ 3,717,924.13	\$ 3,717,924.13	\$ -	\$ -	\$ -
Masters	2024	February	\$ 1,428,552.26	\$ -	\$ -	\$ -	\$ 1,428,552.26
Walmart	2024	February	\$ 12,247,794.12	\$ -	\$ -	\$ -	\$ 12,247,794.12
Walmart	2024	March	\$ 19,016,311.93	\$ -	\$ -	\$ -	\$ 19,016,311.93
Distributors Prepayment	2024	April	\$ 5,730,223.57	\$ -	\$ 950,232.70	\$ -	\$ 4,779,990.87
Walmart (State Costs Fund)	2024	April	\$ 1,804,801.89	\$ 1,804,801.89	\$ -	\$ -	\$ -
Masters	2024	May	\$ 85,553.64	\$ -	\$ 19,830.45	\$ -	\$ 65,723.19
Distributors	2024	July	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2024	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Allergan (Fees)	2024	July	\$ 3,287,105.21	\$ -	\$ 3,287,105.21	\$ -	\$ -
Teva	2024	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
CVS	2024	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2024	August	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
McKinsey MDL (Local Govts)	2024	October	\$ 2,281,342.83	\$ -	\$ -	\$ -	\$ 2,281,342.83
Publicis	2024	November	\$ 4,122,056.40	\$ -	\$ 955,448.77	\$ -	\$ 3,166,607.63
Endo (Bankruptcy)	2024	November	\$ 3,808,546.82	\$ -	\$ -	\$ -	\$ 3,808,546.82
Walmart (Costs)	2024	November	\$ 1,510,167.63	\$ 1,510,167.63	\$ -	\$ -	\$ -
Walmart (Fee Funds)	2024	December	\$ 2,257,158.79	\$ -	\$ 2,257,158.79	\$ -	\$ -
Walgreens	2024	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Walgreens (Fees)	2024	December	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Walmart	2025	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Kroger	2025	March	\$ 1,928,923.84	\$ 500,000.00	\$ 562,998.69	\$ -	\$ 865,925.15
Janssen - J&J	2025	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2025	April	\$ 2,675,439.64	\$ -	\$ 443,663.37	\$ -	\$ 2,231,776.27
Distributors	2025	July	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2025	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2025	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
CVS	2025	August	\$ 15,185,877.23	\$ -	\$ -	\$ 1,422,917.12	\$ 13,762,960.11
CVS (Fees)	2025	August	\$ 14,713,742.58	\$ -	\$ 14,713,742.58	\$ -	\$ -
Walgreens	2025	December	\$ 14,596,002.43	\$ -	\$ -	\$ 3,021,940.98	\$ 11,574,061.45
Walgreens (Fees)	2025	December	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Walmart	2026	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Kroger	2026	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2026	July	\$ 13,018,868.99	\$ -	\$ 2,158,895.73	\$ -	\$ 10,859,973.26
Allergan	2026	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2026	July	\$ 7,000,000.00	\$ -	\$ -	\$ 2,014,627.32	\$ 4,985,372.68
CVS	2026	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2026	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Walgreens (Fees)	2026	December	\$ 16,514,990.87	\$ -	\$ 16,514,990.87	\$ -	\$ -
Walmart	2027	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Kroger	2027	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2027	July	\$ 4,960,189.09	\$ -	\$ 822,539.29	\$ -	\$ 4,137,649.80
Allergan	2027	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2027	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2027	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2027	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2027	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Walgreens (Fees)	2027	December	\$ 16,514,990.88	\$ -	\$ 16,514,990.88	\$ -	\$ -
Walmart	2028	February	\$ 241,732.78	\$ -	\$ -	\$ -	\$ 241,732.78
Kroger	2028	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Kroger (Additional Pay)	2028	March	\$ 89,060.54	\$ -	\$ 20,643.32	\$ -	\$ 68,417.22
Distributors	2028	July	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Allergan	2028	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2028	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2028	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2028	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2028	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2029	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Kroger (Additional Pay)	2029	March	\$ 89,060.54	\$ -	\$ 20,643.32	\$ -	\$ 68,417.22
Distributors	2029	July	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Allergan	2029	July	\$ 3,786,987.57	\$ -	\$ 383,282.32	\$ -	\$ 3,403,705.25
Teva	2029	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2029	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2029	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2029	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2030	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2030	July	\$ 15,311,758.47	\$ -	\$ 2,539,121.46	\$ -	\$ 12,772,637.01
Teva	2030	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2030	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2030	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2030	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2031	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2031	July	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2031	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2031	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2031	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2031	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2032	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2032	July	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2032	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2032	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
CVS	2032	August	\$ 15,185,877.23	\$ -	\$ -	\$ -	\$ 15,185,877.23
Walgreens	2032	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2033	March	\$ 2,428,923.84	\$ -	\$ 562,998.69	\$ -	\$ 1,865,925.15
Distributors	2033	July	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2033	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2033	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Walgreens	2033	December	\$ 14,596,002.43	\$ -	\$ -	\$ -	\$ 14,596,002.43
Kroger	2034	March	\$ 2,428,923.79	\$ -	\$ 562,998.68	\$ -	\$ 1,865,925.11
Distributors	2034	July	\$ 12,871,078.28	\$ -	\$ 2,134,387.83	\$ -	\$ 10,736,690.45
Teva	2034	July	\$ 1,495,003.04	\$ -	\$ -	\$ -	\$ 1,495,003.04
Teva (Fees)	2034	July	\$ 5,504,996.96	\$ -	\$ 5,504,996.96	\$ -	\$ -
Walgreens	2034	December	\$ 14,596,002.43	\$ -			

EXHIBIT B - CHART 2

Allocation Summary for Signatories to the One Nevada Agreement - Actual and Estimated (Revised 01-01-2025)						
State of Nevada - Actual and Estimated Allocations to the Fund for a Resilient Nevada						
(assumes no default in payments)						
(CMS Medicaid costs, if any, not deducted)						
(assumes no administrative fees for court appointed third-party administrators)						
Settlement/Bankruptcy Name	Estimated/Actual Recovery Year	Estimated/Actual Recovery Month	Recoveries Allocation	Costs	Attorney Fees	Net Allocation
McKinsey (State)	2021	September	\$ 28,461,750.49	\$ 16,538,249.51	\$ 5,407,732.59	\$ 6,515,768.39
Janssen - J&J	2022	April	\$ 18,612,345.20	\$ -	\$ 3,536,345.59	\$ 15,075,999.61
Distributors	2022	August	\$ 4,340,895.22	\$ -	\$ 824,770.09	\$ 3,516,125.13
Distributors	2022	September	\$ 4,562,069.29	\$ -	\$ 866,793.17	\$ 3,695,276.12
American Drug Stores	2022	November	\$ 657,900.01	\$ -	\$ 131,580.00	\$ 526,320.01
Mallinckrodt (Bankruptcy)	2022	November	\$ 811,293.19	\$ -	\$ 162,258.64	\$ 649,034.55
Mallinckrodt (Bankruptcy)	2022	November	\$ 17.58	\$ -	\$ -	\$ 17.58
Distributors	2023	July	\$ 4,562,069.29	\$ -	\$ 866,793.17	\$ 3,695,276.12
Allergan	2023	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
CVS (Costs)	2023	August	\$ -	\$ -	\$ -	\$ -
CVS	2023	August	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2023	August	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Mallinckrodt (Bankruptcy)	2023	October	\$ -	\$ -	\$ (162,258.64)	\$ 162,258.64
Mallinckrodt (Bankruptcy)	2023	December	\$ 954,483.23	\$ -	\$ -	\$ 954,483.23
Walgreens	2023	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Masters	2024	February	\$ 626,563.03	\$ -	\$ 134,711.05	\$ 491,851.98
Walmart	2024	February	\$ 5,371,882.50	\$ -	\$ -	\$ 5,371,882.50
Walmart	2024	March	\$ 8,340,554.42	\$ -	\$ -	\$ 8,340,554.42
Distributors Prepayment	2024	April	\$ 2,513,276.09	\$ -	\$ 477,522.46	\$ 2,035,753.63
Masters	2024	May	\$ 37,523.81	\$ -	\$ 8,067.62	\$ 29,456.19
Distributors	2024	July	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
Allergan	2024	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Allergan (Fees)	2024	July	\$ 1,458,406.49	\$ -	\$ 1,458,406.49	\$ -
Teva	2024	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2024	August	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2024	August	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Publicis	2024	November	\$ 1,807,933.95	\$ -	\$ 388,705.80	\$ 1,419,228.15
Endo (Bankruptcy)	2024	November	\$ 1,670,428.65	\$ -	\$ -	\$ 1,670,428.65
Walmart (Fee Funds)	2024	December	\$ 989,989.85	\$ -	\$ 989,989.85	\$ -
Walgreens	2024	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2024	December	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -
Walmart	2025	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Kroger	2025	March	\$ 846,025.98	\$ -	\$ 181,895.59	\$ 664,130.39
Kroger	2025	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Janssen - J&J	2025	April	\$ 1,173,447.81	\$ -	\$ 222,955.08	\$ 950,492.73
Distributors	2025	July	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
Allergan	2025	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2025	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2025	August	\$ 6,877,247.99	\$ -	\$ -	\$ 6,877,247.99
CVS (Fees)	2025	August	\$ 5,731,040.01	\$ -	\$ 5,731,040.01	\$ -
Walgreens	2025	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2025	December	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -
Walmart	2026	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Kroger	2026	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2026	July	\$ 5,710,075.94	\$ -	\$ 1,084,914.43	\$ 4,625,161.51
Allergan	2026	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2026	July	\$ 3,137,299.63	\$ -	\$ -	\$ 3,137,299.63
CVS	2026	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2026	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2026	December	\$ 6,718,803.74	\$ -	\$ 6,718,803.74	\$ -
Walmart	2027	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Kroger	2027	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2027	July	\$ 2,175,538.93	\$ -	\$ 413,352.40	\$ 1,762,186.53
Allergan	2027	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2027	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2027	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2027	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2027	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Walgreens (Fees)	2027	December	\$ 6,718,803.75	\$ -	\$ 6,718,803.75	\$ -
Walmart	2028	February	\$ 106,024.00	\$ -	\$ -	\$ 106,024.00
Kroger	2028	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Kroger (Additional Pay)	2028	March	\$ 39,061.95	\$ -	\$ 8,398.32	\$ 30,663.63
Distributors	2028	July	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19
Allergan	2028	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2028	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2028	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2028	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2028	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2029	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Kroger (Additional Pay)	2029	March	\$ 39,061.95	\$ -	\$ 8,398.32	\$ 30,663.63
Distributors	2029	July	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19
Allergan	2029	July	\$ 1,660,972.77	\$ -	\$ 123,850.76	\$ 1,537,122.01
Teva	2029	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2029	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2029	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2029	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2030	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2030	July	\$ 6,715,737.27	\$ -	\$ 1,275,990.08	\$ 5,439,747.19
Teva	2030	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2030	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2030	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2030	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2031	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2031	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2031	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2031	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2031	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2031	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2032	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2032	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2032	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2032	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
CVS	2032	August	\$ 6,877,248.00	\$ -	\$ -	\$ 6,877,248.00
Walgreens	2032	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2033	March	\$ 1,065,325.99	\$ -	\$ 229,045.09	\$ 836,280.90
Distributors	2033	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2033	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2033	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Walgreens	2033	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Kroger	2034	March	\$ 1,065,325.96	\$ -	\$ 229,045.08	\$ 836,280.88
Distributors	2034	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2034	July	\$ 670,038.92	\$ -	\$ -	\$ 670,038.92
Teva (Fees)	2034	July	\$ 2,239,601.24	\$ -	\$ 2,239,601.24	\$ -
Walgreens	2034	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2035	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2035	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Walgreens	2035	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2036	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2036	July	\$ 3,137,299.64	\$ -	\$ -	\$ 3,137,299.64
Walgreens	2036	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2037	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2037	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Walgreens	2037	December	\$ 6,541,719.00	\$ -	\$ -	\$ 6,541,719.00
Distributors	2038	July	\$ 5,645,254.94	\$ -	\$ 1,072,598.44	\$ 4,572,656.50
Teva	2038	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2039	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2040	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2041	July	\$ 4,033,670.95	\$ -	\$ -	\$ 4,033,670.95
Teva	2042	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Teva	2043	July	\$ 12,101,012.85	\$ -	\$ -	\$ 12,101,012.85
Subtotals Recoveries			\$ 489,496,763.19	\$ 16,538,249.51	\$ 96,732,469.77	\$ 376,226,043.91
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,361,047.44	\$ -	\$ 2,361,047.44	\$ -
Janssen - J&J (State Fee Fund)	2023	June	\$ 2,242,797.39	\$ -	\$ 2,242,797.39	\$ -
Distributors (State Fee Fund)	2023	August	\$ 15,432,662.80	\$ -	\$ 15,432,662.80	\$ -
Janssen - J&J (State Fee Fund)	2023	September	\$ 64,306.55	\$ -	\$ 64,306.55	\$ -
Janssen - J&J (State Fee Fund)	2023	December	\$ 91.31	\$ -	\$ 91.31	\$ -
Distributors (State Fee Fund)	2023	December	\$ 735,956.63	\$ -	\$ 735,956.63	\$ -
Distributors (State Fee Fund)	2023	December	\$ 566,547.35	\$ -	\$ 566,547.35	\$ -
Distributors (State Fee Fund)	2023	December	\$ 589,362.17	\$ -	\$ 589,362.17	\$ -
Distributors (State Costs Fund)	2024	April	\$ 7,198,279.03	\$ 7,198,279.03	\$ -	\$ 7,198,279.03
Janssen - J&J (State Costs Fund)	2024	April	\$ 1,160.73	\$ 1,160.73	\$ -	\$ -
Distributors (State Fee Fund)	2024	July	\$ 1,774.22	\$ -	\$ 1,774.22	\$ -
Janssen - J&J (State Fee Fund)	2024	August	\$ 302,274.45	\$ -	\$ 302,274.45	\$ -
Publicis (State Costs Fund)	2024	November	\$ 5,000.00	\$ 5,000.00	\$ -	\$ -
Endo (State Costs Fund)	2024	November	\$ 166,541.42	\$ 166,541.42	\$ -	\$ -
Subtotals Funds			\$ 29,667,801.49	\$ 7,370,981.18	\$ 22,296,820.31	\$ 29,667,801.49
			\$ 519,164,564.68	\$ 9,167,268.33	\$ 74,435,649.46	\$ 405,893,845.40
			Total Recoveries	Total Costs	Total Attorney Fees	Total Net Allocation